Biotech Stock News (CLDX) (SRPT)

Celldex Therapeutics (NASDAQ:CLDX) On Monday March 7, 2016 shares of Celldex fell as much as 53% after the company announced that it had to discontinue a phase 3 trial. The reason for discontinuing the trial was because of insufficient efficacy needed to move on. This phase 3 trial recruited a total of 745 patients who … Read more

Tuesday Talk: Biotech News 2/23/15 to 2/27/15

Valeant Pharmaceuticals (VRX) & Salix Pharmaceuticals (SLXP) Valeant Pharmaceuticals had agreed to buy Salix Pharmaceuticals for about $10.4 billion dollars in an all cash type deal. Valeant currently has many approved drugs in various areas such as: skin, eyes, and oral type drugs. This addition of Salix Pharmaceuticals will give Valeant access to a gastrointestinal … Read more